Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goserelin implant - AMW/Alvogen

Drug Profile

Goserelin implant - AMW/Alvogen

Alternative Names: Reseligo

Latest Information Update: 25 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AMW GmbH
  • Developer Alvogen; AMW GmbH
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Prostate cancer; Uterine diseases; Uterine leiomyoma

Most Recent Events

  • 10 Mar 2021 Phase III trial for Prostate cancer is still ongoing in Germany (EudraCT2010-018735-18)
  • 10 Mar 2021 Phase-III clinical trials in Prostate cancer in Germany (SC)
  • 22 Jan 2019 Goserelin implant is not yet available for Breast cancer, Endometriosis, Female infertility, Prostate cancer, Uterine diseases and Uterine leiomyoma in Portugal, Slovakia, Slovenia and Czech Republic
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top